Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | POLRMT | O00411 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.30 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23047661 | 1.00 | ACVRL1 (0.32) | ACVRL1PIK3CDPOLRMTRIPK1TMPRSS2 | |
| SCHEMBL18666834 | 1.00 | ACVRL1 (0.32) | ACVRL1PIK3CDPOLRMTRIPK1TMPRSS2 | |
| SCHEMBL24790993 | 0.84 | TMPRSS2 (0.36) | TMPRSS2 | |
| SCHEMBL24789459 | 0.83 | RIPK1 (0.33) | PIK3CDPOLRMTRIPK1 | |
| SCHEMBL4971072 | 0.82 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL24789410 | 0.82 | RIPK1 (0.32) | ACVRL1RIPK1TMPRSS2 | |
| SCHEMBL4970753 | 0.81 | TMPRSS2 (0.36) | ACVRL1PIK3CDTMPRSS2TNK2 | |
| SCHEMBL10142076 | 0.81 | TMPRSS2 (0.36) | ACVRL1PIK3CDTMPRSS2TNK2 | |
| SCHEMBL18666907 | 0.81 | TMPRSS2 (0.36) | ACVRL1PIK3CDTMPRSS2TNK2 | |
| SCHEMBL18666854 | 0.81 | TNK2 (0.35) | TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054618-A1 | METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-4130001-A1 | PROCESS FOR THE DIRECT CATALYTIC GLYCOSYLATION OF ARENES | Studiengesellschaft Kohle mbH (DE) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022265964-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2022-12-22 | — | — | WO | disclosed |
| EP-3785717-B1 | METHODS FOR TREATING CORONAVIRIDAE INFECTIONS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-3212175-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2021183750-A2 | METHODS OF PREPARING 1'-CYANO NUCLEOSIDES | GILEAD SCIENCES, INC. (US) | 2021-09-16 | — | — | WO | disclosed |
| EP-3785717-A1 | METHODS FOR TREATING CORONAVIRIDAE INFECTIONS | Gilead Sciences, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| WO-2017184668-A1 | METHODS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017049060-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20120107274-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2012037038-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-8008264-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107274-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NUDT1, SLC29A2 | ACVRL1 2646/4885PIK3CD 273/4885POLRMT 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.